Combined anti-amyloid (lecanemab/donanemab) and anti-tau (gosuranemab/tilavonemab) immunotherapy will demonstrate synergistic disease-modifying effects compared to monotherapy in early-stage Alzheimer's disease, with greater preservation of cognition and reduced neurodegeneration.
This experiment tests whether dual targeting of Aβ and tau pathologies produces synergistic benefits beyond what either monotherapy can achieve alone. Current trials test each pathway independently — this addresses the critical gap of whether combination therapy is safe and effective.
Population: Early AD (MCI due to AD or mild AD dementia), ages 60-85, amyloid PET positive, tau PET positive
Sample Size: 450 participants (150 per arm)
Duration: 24 months treatment, 12 months follow-off
| Item | Cost (USD) |
|---|---|
| Study drug (lecanemab) | $2,400,000 |
| Study drug (anti-tau) | $1,800,000 |
| MRI scans (baseline + 4) | $450,000 |
| PET scans (amyloid + tau) | $900,000 |
| Plasma biomarkers | $180,000 |
| CSF collection | $300,000 |
| Clinical assessments | $450,000 |
| Site management | $600,000 |
| Data management | $300,000 |
| Statistical analysis | $150,000 |
| Subtotal | $7,530,000 |
| Phase | Duration | Activities |
|---|---|---|
| Startup | 6 months | IRB, sites, supply chain |
| Recruitment | 12 months | Enrollment of 450 participants |
| Treatment | 24 months | Dosing and assessments |
| Follow-off | 12 months | Safety monitoring |
| Analysis | 6 months | Data lock to report |
| Total | 60 months (5 years) | — |
| Dimension | Score (1-10) | Rationale |
|---|---|---|
| Scientific value | 9 | Tests synergistic dual-targeting hypothesis |
| Clinical relevance | 10 | Direct impact on treatment paradigm |
| Feasibility | 7 | Complex but doable at specialized centers |
| Discriminative power | 9 | Can distinguish monotherapy vs combo |
| Novelty | 10 | First large combo trial |
| Cost-efficiency | 6 | Expensive but comprehensive |
| Timeline | 5 | 5 years is lengthy but necessary |
| Safety monitoring | 7 | ARIA risk manageable |
| Regulatory path | 8 | Clear pathway with existing approvals |
| Global applicability | 9 | Multi-regional design |
Composite Score: 7.8 / 10
| Risk | Likelihood | Mitigation |
|---|---|---|
| ARIA (ARIA-E/H) | Medium | Strict inclusion, weekly monitoring |
| Drug-drug interactions | Low | PK sampling in subset |
| Recruitment challenges | Medium | Multi-continental sites |
| Dropout | Medium | Retention incentives |
This page provides information about AD Combination Therapy Trial: Anti-Aβ + Anti-Tau.